Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The EINSTEIN CYP Cohort Study Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep-vein Thrombosis or Pulmonary Embolism Using a Strong CYP 3A4 Inducer

NCT00786422 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT00786422
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00786422 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The EINSTEIN CYP Cohort Study Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep-vein Thrombosis or Pulmonary Embolism Using a Strong CYP 3A4 Inducer
Lead sponsor
Bayer
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2009
Completion date
June 30, 2011
Enrollment
25 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

deep vein thrombosis, venous thrombosis